Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.
Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, Boyle F, McCune S, Armstrong A, Shannon C, Bertelli G, Chang CW, Desai R, Gupta K, Wilson TR, Flechais A, Bardia A. Lindeman GJ, et al. Among authors: gupta k. Clin Cancer Res. 2022 Aug 2;28(15):3256-3267. doi: 10.1158/1078-0432.CCR-21-3811. Clin Cancer Res. 2022. PMID: 35583555 Free PMC article. Clinical Trial.
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
Hamilton EP, Kaklamani V, Falkson C, Vidal GA, Ward PJ, Patre M, Chui SY, Rotmensch J, Gupta K, Molinero L, Li Y, Emens LA. Hamilton EP, et al. Among authors: gupta k. Clin Breast Cancer. 2021 Dec;21(6):539-551. doi: 10.1016/j.clbc.2021.04.011. Epub 2021 May 15. Clin Breast Cancer. 2021. PMID: 34154926 Clinical Trial.
Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.
Gligorov J, Pivot X, Ataseven B, De Laurentiis M, Jung KH, Manikhas A, Abdel Azim H, Gupta K, Alexandrou A, Herraez-Baranda L, Tosti N, Restuccia E. Gligorov J, et al. Among authors: gupta k. Breast. 2022 Aug;64:151-158. doi: 10.1016/j.breast.2022.03.001. Epub 2022 Mar 17. Breast. 2022. PMID: 35487845 Free PMC article.
Low-dose methotrexate in Rheumatology: A reinvented drug.
Gupta K, Ravindran V. Gupta K, et al. J R Coll Physicians Edinb. 2025 Jan 10:14782715241312256. doi: 10.1177/14782715241312256. Online ahead of print. J R Coll Physicians Edinb. 2025. PMID: 39791321 Review.
Solution biophysics identifies lipid nanoparticle non-sphericity, polydispersity, and dependence on internal ordering for efficacious mRNA delivery.
Padilla MS, Shepherd SJ, Hanna AR, Kurnik M, Zhang X, Chen M, Byrnes J, Yamagata HM, Ricciardi A, Joseph RA, Mrksich K, Issadore D, Gupta K, Mitchell MJ. Padilla MS, et al. Among authors: gupta k. bioRxiv [Preprint]. 2024 Dec 22:2024.12.19.629496. doi: 10.1101/2024.12.19.629496. bioRxiv. 2024. PMID: 39763759 Free PMC article. Preprint.
4,368 results